ATS 2020 Advance Program

• how to adapt clinical practice guidelines in countries with diverse capabilities; • understand the impact of climate change on lung disease and steps to take to advocate for improved lung health. This session will look at lung diseases as a whole and the challenges faced by patients and providers globally. We will address the importance of advocacy, patient, and clinician involvement on a worldwide scale, examining case studies where advocates and clinicians played a direct role in improving the standard of care internationally. With this goal comes significant challenges, such as technological discrepancies and understanding the impact of climate change on global lung health. We hope to get these important discussions started. Chairing: K.L. Rosbeck, BA, Silver Spring, MD D. Gozal, MD, MBA, ATSF, Columbia, MO 9:15 PAR Awards Presentation K.L. Rosbeck, BA, Silver Spring, MD 9:20 Global Patient Advocacy and Lessons from the Global Respiratory Summit T. Winders, MBA, Vienna, VA 9:27 Lung Function Trajectories in Health and Disease: The Patient Advocate’s Role in Improving Respiratory Health A. Agusti, MD, Barcelona, Spain 9:45 International Patient Registries and the Importance of Coordinating Globally: Pulmonary Fibrosis as a Case Study G.P. Cosgrove, MD, Denver, CO 10:03 International Clinical Collaborations to Advance New Treatments: LAM and Approval of Sirolimus as a Case Study N. Gupta, MD, Cincinnati, OH 10:21 Global Clinical Practice Guidelines for Standards of Care with Diverse Capabilities K.C. Wilson, MD, ATSF, New York, NY 10:39 Case Study: Global Clinical Practice Guidelines for Sleep Apnea in Children and Adults D. Gozal, MD, MBA, ATSF, Columbia, MO 10:57 Climate Change and Impact on Global Lung Health: What You Can Do to Make a Difference M.B. Rice, MD, MPH, Boston, MA BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM C11 EVOLVING KNOWLEDGE OF THE EFFECT OF CANNABIS AND CANNABINOIDS ON THE LUNG Assemblies on Environmental, Occupational and Population Health; Pediatrics; Respiratory Structure and Function; Tobacco Action Committee; Drug/Device Discovery and Development Committee 9:15 a.m. - 11:15 a.m. Target Audience Clinical providers, basic scientists, clinical researchers, translational researchers, nurses, respiratory therapists. Objectives At the conclusion of this session, the participant will be able to: • learn about the emerging data regarding the effect of different routes of cannabis use on lung health; • improve knowledge of the mechanisms of cannabis effects in human, animal and in vitro models; Cannabis and cannabidiol (CBD) are now legally available in Canada, and in an increasing number of U.S. states for medical use or recreational use. Despite increasing availability, there is little scientific information about how cannabis affects lung health in the short or long term. This session will feature basic scientists using cellular and animal models as well as clinical and translational researchers shedding light on how cannabis use affects the lung. Chairing: K.L. Bailey, MD, ATSF, Omaha, NE L.E. Crotty Alexander, MD, ATSF, San Diego, CA 9:15 Patterns of Cannabis and Cannabinoid Use K. Wilson, MD, MPH, New York, NY ATS 2020 • Philadelphia, PA TUESDAY • MAY 19 107